Nature Communications (Apr 2022)
Ubiquitin-like protein 3 (UBL3) is required for MARCH ubiquitination of major histocompatibility complex class II and CD86
- Haiyin Liu,
- Kayla R. Wilson,
- Ashley M. Firth,
- Christophe Macri,
- Patrick Schriek,
- Annabelle B. Blum,
- Javiera Villar,
- Samuel Wormald,
- Mitch Shambrook,
- Bangyan Xu,
- Hui Jing Lim,
- Hamish E. G. McWilliam,
- Andrew F. Hill,
- Laura E. Edgington-Mitchell,
- Irina Caminschi,
- Mireille H. Lahoud,
- Elodie Segura,
- Marco J. Herold,
- Jose A. Villadangos,
- Justine D. Mintern
Affiliations
- Haiyin Liu
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- Kayla R. Wilson
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- Ashley M. Firth
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- Christophe Macri
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- Patrick Schriek
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- Annabelle B. Blum
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- Javiera Villar
- Institut Curie, PSL Research University, INSERM, U932
- Samuel Wormald
- The Walter and Eliza Hall Institute of Medical Research
- Mitch Shambrook
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University
- Bangyan Xu
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- Hui Jing Lim
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne
- Hamish E. G. McWilliam
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- Andrew F. Hill
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University
- Laura E. Edgington-Mitchell
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- Irina Caminschi
- Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University
- Mireille H. Lahoud
- Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University
- Elodie Segura
- Institut Curie, PSL Research University, INSERM, U932
- Marco J. Herold
- The Walter and Eliza Hall Institute of Medical Research
- Jose A. Villadangos
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- Justine D. Mintern
- Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute
- DOI
- https://doi.org/10.1038/s41467-022-29524-w
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
Regulated trafficking of major histocompatibility complex class II and CD86 is a prerequisite of antigen presenting cell functionality. Authors show here that ubiquitin-like protein 3 is critically involved in the ubiquitination process that controls trafficking, with wide-ranging immunological consequences.
